Bank Pictet & Cie Europe AG Has $4.35 Million Stake in Boston Scientific Co. (NYSE:BSX)

Bank Pictet & Cie Europe AG lowered its position in Boston Scientific Co. (NYSE:BSX) by 34.6% in the third quarter, HoldingsChannel.com reports. The fund owned 51,923 shares of the medical equipment provider’s stock after selling 27,416 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Boston Scientific were worth $4,351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Park Avenue Securities LLC grew its holdings in Boston Scientific by 12.8% during the first quarter. Park Avenue Securities LLC now owns 12,435 shares of the medical equipment provider’s stock worth $852,000 after purchasing an additional 1,413 shares during the period. Brookstone Capital Management increased its holdings in shares of Boston Scientific by 35.0% during the 1st quarter. Brookstone Capital Management now owns 14,300 shares of the medical equipment provider’s stock worth $979,000 after acquiring an additional 3,710 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Boston Scientific by 10.9% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 66,024 shares of the medical equipment provider’s stock valued at $4,522,000 after acquiring an additional 6,485 shares during the period. Tlwm acquired a new stake in Boston Scientific during the 1st quarter valued at $927,000. Finally, 180 Wealth Advisors LLC boosted its position in Boston Scientific by 36.5% during the first quarter. 180 Wealth Advisors LLC now owns 5,621 shares of the medical equipment provider’s stock worth $385,000 after purchasing an additional 1,504 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares in the company, valued at $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 316,253 shares of company stock worth $26,714,298. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Raymond James increased their price objective on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research report on Wednesday, September 4th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Barclays boosted their price target on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Thursday, August 22nd. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $90.68.

Boston Scientific Stock Down 0.0 %

Shares of NYSE BSX opened at $88.02 on Wednesday. The company has a market cap of $129.13 billion, a price-to-earnings ratio of 73.97, a PEG ratio of 2.87 and a beta of 0.80. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12 month low of $49.15 and a 12 month high of $88.79. The stock has a 50-day moving average price of $82.97 and a two-hundred day moving average price of $77.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the prior year, the company earned $0.53 EPS. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.